Lexeo Therapeutics, Inc. (LXEO) Form 8-K — Sep 22, 2026
Lexeo Therapeutics (Nasdaq: LXEO) entered into a merger agreement on September 16, 2026 to acquire Mantle Therapeutics via its merger subsidiary, with Mantle surviving as a wholly owned subsidiary. Consideration is $8.3 million upfront — $5.3 million cash and $3.0 million in unregistered Lexeo common stock — plus a potential $1.0 million additional cash payment and up to $12 million in development and regulatory milestones over a 12-year term, none of which is guaranteed. The deal received written consents from Key Stockholders holding roughly 76.1% of Mantle's capital stock, and either party may terminate if closing does not occur by November 16, 2026.
Key figures
- Expense fund
- $250,000
- Outside date
- November 16, 2026
- Upfront cash
- $5,300,000
- Escrow amount
- $830,000
- Upfront stock
- $3,000,000
- Parent stock price
- $4.74
- Clarity fa enrollment
- 22 participants enrolled or imminently enrolling
- Max milestone payments
- $12,000,000 over a 12-year milestone term
- Additional cash payment
- $1,000,000
- Key stockholders support
- approximately 76.1% of capital stock / 83.5% of preferred
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.